<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335863">
  <stage>Registered</stage>
  <submitdate>18/08/2010</submitdate>
  <approvaldate>18/08/2010</approvaldate>
  <actrnumber>ACTRN12610000682044</actrnumber>
  <trial_identification>
    <studytitle>Flucloxacillin in Cellulitis: A randomised controlled trial comparing continuous infusion to bolus dosing for uncomplicated cellulitis.</studytitle>
    <scientifictitle>In an adult population with uncomplicated cellulitis presenting to an Emergency Department is flucloxacillin delivered by infusion comparable to bolus dosing for nursing workload and patient discharge at 24 hours?</scientifictitle>
    <utrn />
    <trialacronym>FliC</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cellulitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Efficacy of 8g Flucloxacillin administered continuously via infusion over 24 hours</interventions>
    <comparator>Four six hourly intravenous 2g boluses of Flucloxacillin over 24 hours</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Nursing time in preparing and administering drug measured with a stopwatch by an independent observer</outcome>
      <timepoint>First 24 hours of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Patient and Nurse satisfaction as measured by a written questionnaire</outcome>
      <timepoint>At 24 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients discharged on oral antibiotics at 24 hours as documented in the patient record.</outcome>
      <timepoint>24 hours after admission</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum flucloxacillin levels</outcome>
      <timepoint>16 hours after first antibiotic dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with cellulitis felt to be clinically suitable for management in an Emergency Department Short Stay Unit.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Abbreviated Mortality in Emergency Department Sepsis Score &gt;4		
Physician intends to treat with other than Flucloxacillin 2G Intravenously four times daily
Patient has any of the following comorbidities:
*Diabetes Mellitus
*Chronic Systemic Steroid Use	
*Immunosuppression
Patient will not be contactable by telephone for next 31 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/10/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4029</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Brisbane &amp; Women's Hospital</primarysponsorname>
    <primarysponsoraddress>Butterfield Street,
Herston
Qld 4029</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Queensland Emergency Medicine Research Foundation</fundingname>
      <fundingaddress>c/o Australian Medical Association Queensland,
88 L'Estrange Tce, Red Hill, Queensland 4059
PO Box 123, Red Hill, QLD 4059</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to test the hypothesis that by managing Emergency Department patients with uncomplicated cellulitis in a short stay unit with a continuous 24 hour infusion of 8g of intravenous flucloxacillin as opposed to the current standard treatment of four 2g intravenous blouses administered every six hours for 24 hours, significant nursing time and resources would be saved with there being no decrease in the clinical or microbiological cure rate of the cellulitis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane &amp; Women's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Royal Brisbane &amp; Women's Hospital
Butterfield Street
Herston 
QLD 4029</ethicaddress>
      <ethicapprovaldate>27/07/2010</ethicapprovaldate>
      <hrec>HREC/10/QRBW/137</hrec>
      <ethicsubmitdate>19/04/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Peter Logan</name>
      <address>Department of Emergency Medicine
Royal Brisbane &amp; Women's Hospital
Butterfield Street
Herston
Qld 4029</address>
      <phone>+61736368111</phone>
      <fax />
      <email>peter_logan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Peter Logan</name>
      <address>Department of Emergency Medicine
Royal Brisbane &amp; Women's Hospital
Butterfield Street
Herston
Qld 4029</address>
      <phone>+61736368111</phone>
      <fax />
      <email>peter_logan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Peter Logan</name>
      <address>Department of Emergency Medicine
Royal Brisbane &amp; Women's Hospital
Butterfield Street
Herston
Qld 4029</address>
      <phone>+61736368111</phone>
      <fax />
      <email>peter_logan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>